TITLE

A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies

AUTHOR(S)
Hahn, K.; Arendt, G.; Braun, J. S.; von Giesen, H.-J.; Husstedt, I. W.; Maschke, M.; Straube, E.; Schielke, E.
PUB. DATE
October 2004
SOURCE
Journal of Neurology;Oct2004, Vol. 251 Issue 10, p1260
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background Painful HIV-associated sensory neuropathies (HIV-SN) are a common complication of HIV infection. The pathogenesis is unknown and the treatment very limited. Gabapentin (GBP) is effective in painful diabetic neuropathy and postherpetic neuralgia and its effectiveness on painful HIV-SN has been reported anecdotally. Design Multicenter, prospective, randomised, double-blind, placebo-controlled study. Methods Patients were followed for a 1-week screening, a 4-week double- blind and a 2-week open treatment phase. GBP was initiated at 400 mg/d, titrated over 2 weeks to 1200 mg/d, and then either maintained at this level or - if not beneficial - titrated to 2400 mg/d. After 4 weeks the medication was unblinded and the patient had the choice to begin, to maintain or to increase GBP to 3600 mg/d. The primary outcome measure was an improvement in median pain on the Visual Analogue Scale (VAS) from the screening week compared to the 4th treatment week. A secondary efficacy measure was the median sleep score (VAS). Results 15 patients received GBP and 11 placebo. In each group one patient dropped out during the double-blind phase. Median pain (GBP 5.1; placebo 4.7) and sleep score (GBP 4.5; placebo 5.6) did not differ between both groups at baseline. In the GBP-group there was a significant decrease of the pain to 2.85 (-44.1 %) as well as of the sleep VAS to 2.3 (-48.9 %). No significant decrease in the pain (median VAS = 3.3, -29.8 %) as well as in the sleep score (median VAS = 4.95, -11.6 %) was observed in the placebo-group. GBP was generally well tolerated. The most frequent side effect was somnolence reported in 80% of GBP-treated patients. Conclusions GBP was more effective than placebo in reducing pain and sleep interference in patients with HIV-SN.
ACCESSION #
15398676

 

Related Articles

  • Frequency and risk factors for distal sensory polyneuropathy in HIV infection in a developing country. Ekenze, Oluchi S; Nwosu, Cosmas M; Ogunniyi, Adesola // International Journal of STD & AIDS;Mar2014, Vol. 25 Issue 3, p178 

    Distal sensory polyneuropathy is a source of morbidity in HIV infection. This study aims to determine the frequency and effect of demographic and clinical variables on distal sensory polyneuropathy, among HIV-positive participants in south-east Nigeria. The study involved highly active...

  • Disseminated tuberculosis after extracorporeal shock-wave lithotripsy in an AIDS patient presenting with urosepsis. Tourchi, Ali; Ebadi, Maryam; Hosseinzadeh, Alireza; Shabaninia, Mahsa // International Journal of STD & AIDS;Mar2014, Vol. 25 Issue 3, p231 

    Haematogenous dissemination of undiagnosed urinary tuberculosis after performing extracorporeal shock-wave lithotripsy (ESWL) is extremely rare. Herein, we report a 41-year-old male who presented with urosepsis to the emergency room; catheterization was performed and retention resolved. He had a...

  • Antinociceptive effects of topical mepivacaine in a rat model of HIV-associated peripheral neuropathic pain. Sagen, Jacqueline; Castellanos, Daniel A.; Hama, Aldric T. // Journal of Pain Research;Jun2016, Vol. 9, p361 

    Background: A consequence of HIV infection is sensory neuropathy, a debilitating condition that degrades the quality of life of HIV patients. Furthermore, life-extending antiretroviral treatment may exacerbate HIV sensory neuropathy. Analgesics that relieve other neuropathic pains show little or...

  • superinfection a changing picture. Duffin, Ross // HIV Australia;Jun-Aug2004, Vol. 3 Issue 4, p9 

    Discusses the impact of superinfection on an individual's HIV disease progression. Overview of several HIV superinfection cases in Australia; Frequency of the occurrence of superinfection; Recommended approach to prevent HIV superinfection.

  • Clues from neuropathy. M.O.R. // Cortlandt Forum;06/25/97, Vol. 10 Issue 6, p132 

    Identifies HIV infection and certain antiretroviral drugs as cause of symmetric distal sensory neuropathy. Symptomatic treatment of neuropathy from HIV.

  • Health Economics in HIV Disease: A Review of the European Literature. Youle, M.; Trueman, P.; Simpson, K. // PharmacoEconomics;1999 Supplement 1, Vol. 15 Issue 5, p1 

    The costs of providing healthcare resources for patients with HIV disease have continued to rise during the last 2 decades since the first outbreak of AIDS. Although new and effective therapies have become available during this time, and are increasingly being used, outcome measures for, and the...

  • Accrued HIV evidence turns treatment dogma on its head. Check, Erika // Nature;8/21/2003, Vol. 424 Issue 6951, p866 

    Focuses on the possible health risk posed by HIV drugs in patients. Inefficacy of drugs in subduing virus in HIV positive patients; Comments of various researchers on HIV therapy; Thoughts over the distribution of drugs among various developing countries.

  • The Importance of Potency and Durability in HIV Patient Antiretroviral Therapy Preferences: A Telephone Survey. Sherer Jr., Renslow D.; Fath, Michael J.; Da Silva, Barbara A.; Nicolau, Ana-Maria; Miller, Nancy L. // AIDS Patient Care & STDs;Dec2005, Vol. 19 Issue 12, p794 

    Patients who were receiving or had received antiretroviral therapy (ART) participated in 45-minute telephone interviews to evaluate the importance of major treatment attributes. A Likert scale was used to quantify and rate the importance of 9 ART attributes. Trade-off exercises allowed...

  • Prevalence of Metabolic Syndrome in Patients with HIV in the Era of Highly Active Antiretroviral Therapy. LOMBO, BERNARDO; ALKHALIL, IMRAN; GOLDEN, MARJORIE P.; FOTJADHI, IRMA; RAVI, SREEDHAR; VIRATA, MICHAEL; LIEVANO, MARTA; DIEZ, JOSE; GHANTOUS, ANDRE; DONOHUE, THOMAS // Connecticut Medicine;May2015, Vol. 79 Issue 5, p277 

    Objectives: Since the introduction of combination antiretroviral therapy (cART) as the standard of care for HIV disease, there has been a precipitous decline in the death rate due to HIV/AIDS. The purpose of this study was to report the prevalence of metabolic syndrome in HIV infected patients....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics